TY - JOUR
T1 - Prevalence of mitochondrial gene mutations among hearing impaired patients
AU - Usami, Shin Ichi
AU - Doi, Katsumi
AU - Kubo, Takeshi
AU - Nakagawa, Takashi
AU - Komiyama, Sohtaro
AU - Tono, Tetsuya
AU - Komune, Shizuo
AU - Abe, Satoko
AU - Akita, Jiro
AU - Namba, Atsushi
AU - Shinkawa, Hideichi
AU - Ishii, Masanori
AU - Iwasaki, Satoshi
AU - Hoshino, Tomoyuki
AU - Ito, Juichi
PY - 2000
Y1 - 2000
N2 - The frequency of three mitochondrial point mutations, 1555A→G, 3243A→G, and 7445A→G, known to be associated with hearing impairment, was examined using restriction fragment length polymorphism (RFLP) analysis in two Japanese groups: (1) 319 unrelated SNHL outpatients (including 21 with aminoglycoside antibiotic injection history), and (2) 140 cochlear implantation patients (including 22 with aminoglycoside induced hearing loss). Approximately 3% of the outpatients and 10% of the cochlear implantation patients had the 1555A→G mutation. The frequency was higher in the patients with a history of aminoglycoside injection (outpatient group 33%, cochlear implantation group 59%). One outpatient (0.314%) had the 3243A→G mutation, but no outpatients had the 7445A→G mutation and neither were found in the cochlear implantation group. The significance of the 1555A→G mutation, the most prevalent mitochondrial mutation found in this study of a hearing impaired population in Japan, among subjects with specific backgrounds, such as aminoglycoside induced hearing loss, is evident.
AB - The frequency of three mitochondrial point mutations, 1555A→G, 3243A→G, and 7445A→G, known to be associated with hearing impairment, was examined using restriction fragment length polymorphism (RFLP) analysis in two Japanese groups: (1) 319 unrelated SNHL outpatients (including 21 with aminoglycoside antibiotic injection history), and (2) 140 cochlear implantation patients (including 22 with aminoglycoside induced hearing loss). Approximately 3% of the outpatients and 10% of the cochlear implantation patients had the 1555A→G mutation. The frequency was higher in the patients with a history of aminoglycoside injection (outpatient group 33%, cochlear implantation group 59%). One outpatient (0.314%) had the 3243A→G mutation, but no outpatients had the 7445A→G mutation and neither were found in the cochlear implantation group. The significance of the 1555A→G mutation, the most prevalent mitochondrial mutation found in this study of a hearing impaired population in Japan, among subjects with specific backgrounds, such as aminoglycoside induced hearing loss, is evident.
UR - http://www.scopus.com/inward/record.url?scp=0034054301&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034054301&partnerID=8YFLogxK
U2 - 10.1136/jmg.37.1.38
DO - 10.1136/jmg.37.1.38
M3 - Article
C2 - 10633132
AN - SCOPUS:0034054301
SN - 0022-2593
VL - 37
SP - 38
EP - 40
JO - Journal of Medical Genetics
JF - Journal of Medical Genetics
IS - 1
ER -